Open Life Sciences (Mar 2023)

Radiotherapy for primary thyroid adenoid cystic carcinoma

  • Duan Xiaoyu,
  • Hu Tingting,
  • Cai Hongyi,
  • Lin Lili,
  • Zeng Lu,
  • Wang Huixia,
  • Cao Lei,
  • Li Xuxia

DOI
https://doi.org/10.1515/biol-2022-0547
Journal volume & issue
Vol. 18, no. 1
pp. 367 – 70

Abstract

Read online

Primary thyroid adenoid cystic carcinoma (PTACC) is an extremely rare type of mucin-secreting adenocarcinoma. Currently, it is difficult to diagnose, and it lacks standard treatment protocols. We report the case of a 53-year-old female patient with PTACC who underwent additional intensity-modulated radiotherapy 1 month after surgical treatment with an uneventful course. No invasion or distant metastasis was detected at the 7-month follow-up after radiotherapy, and the prognosis was favorable. In this case, herein, we have summarized the diagnostic features of the disease and proposed that postoperative adjuvant radiotherapy can significantly improve the patient’s prognosis. Finally, we further confirmed the important role of radiotherapy in PTACC by reviewing relevant literature, which may provide clinicians with valuable treatment experience.

Keywords